مقایسه اثرات قرص‌های اتیسترون و کنتراسمین بر یافته‌های بالینی و بیوشیمیایی هیپرآندروژنیسم و پارامترهای متابولیک بیماران مبتلا به سندرم تخمدان پلی‌کیستیک: یک کارآزمایی بالینی تصادفی

نوع مقاله : اصیل پژوهشی

نویسندگان

1 استادیار غدد تولید مثل، مرکز تحقیقات اندوکرینولوژی تولید مثل، پژوهشکده علوم غدد درون‌ریز و متابولیسم شهید بهشتی، دانشکده پزشکی، دانشگاه علوم پزشکی شهید بهشتی، تهران، ایران.

2 دکترای تخصصی آمار زیستی، مرکز تحقیقات اندوکرینولوژی تولید مثل، پژوهشکده علوم غدد درون‌ریز و متابولیسم شهید بهشتی، دانشگاه علوم پزشکی شهید بهشتی، تهران، ایران.

3 دانشیار گروه مامایی و بهداشت باروری، دانشکده پرستاری و مامایی، دانشگاه علوم پزشکی شهید بهشتی، تهران، ایران.

4 استاد غدد تولید مثل، مرکز تحقیقات اندوکرینولوژی تولید مثل، پژوهشکده علوم غدد درون‌ریز و متابولیسم، دانشکده پزشکی، دانشگاه علوم پزشکی شهید بهشتی، تهران، ایران.

چکیده

مقدمه: امروزه انتخاب کنتراسپتیو با بیشترین اثرات ضد آندروژنی، یک چالش مهم در درمان بیماران مبتلا به سندرم تخمدان پلی‌کیستیک (PCOS) است. مطالعه حاضر با هدف مقایسه اثربخشی قرص‌های اتیسترون و کنتراسمین بر پیامدهای PCOS انجام شد.
روش‌کار: این مطالعه کارآزمایی بالینی تصادفی در سال 96-1394 بر روی 108 بیمار مبتلا به PCOS مراجعه‌کننده به درمانگاه غدد پژوهشکده غدد درون‌ریز و متابولیسم دانشگاه علوم پزشکی شهید بهشتی تهران انجام شد. بیماران به‌صورت تصادفی در یکی از گروه‌های مداخله با قرص‌های اتیسترون یا کنتراسمین قرار گرفتند. پیامدهای مورد بررسی شامل: پارامترهای آندروژنیک، بالینی و متابولیک در وضعیت پایه، ماه سوم و ششم درمان بود. اندازه‌گیری‌های بالینی، هورمونی و متابولیک، با استفاده از پرسشنامه‌های استاندارد، ابزارهای بیوفیزیولوژیک و کیت‌های تشخیصی آزمایشگاهی انجام شد. به‌منظور بررسی اختلاف بین دو گروه درمان از مدل آماری معادلات برآورد تعمیم یافته استفاده شد. میزان p کمتر از 05/0 معنی‌دار در نظر گرفته شد.
یافته‌ها: پس از 3 ماه درمان، میزان آندروژن‌ها بین دو گروه درمان تفاوت معنی‌داری نداشت (05/0<p)، در‌‌حالی‌که پس از 6 ماه درمان، میزان تستوسترون در بیماران درمان شده با اتیسترون در مقایسه با کنتراسمین کمتر بود (029/0=p). 3 ماه پس از درمان، پارامترهای متابولیک بین دو گروه تفاوت معنی‌داری نداشتند (05/0<p)، در‌حالی‌که در ماه ششم درمان، بیماران درمان شده با اتیسترون در مقایسه با کنتراسمین میزان تری‌گلیسیرید بیشتری داشتند (049/0=p). در پایان ماه سوم و ششم درمان، فشارخون دیاستولیک در بیماران درمان شده با اتیسترون در مقایسه با کنتراسمین به‌طور معنی‌داری بیشتر بود (05/0>p).
نتیجه‌گیری: مصرف کنتراسپتیوهای حاوی سیپروترون استات در مقایسه با فرآورده‌های حاوی دروسپیرنون با بهبود بییشتر هیپرآندروژنیسم بیوشیمیایی همراه است، در‌حالی‌که این ترکیبات می‌توانند موجب دیس‌لیپیدمی و افزایش فشارخون در بیماران مبتلا به PCOS گردند.

کلیدواژه‌ها

عنوان مقاله [English]

Effects of Etisterone and Contrasmine pills on clinical and biochemical findings of hyperandrogenism and metabolic parameters of patients with polycystic ovary syndrome: A randomized clinical trial

نویسندگان [English]

  • Mina Amiri 1
  • Razieh Bidhendi-Yarandi 2
  • Fatemeh Nahidi 3
  • Fahimeh Ramezani Tehrani 4
1 Assistant Professor, Department of Reproductive Endocrinology, Reproductive Endocrinology Research Center, Shahid Beheshti Research Institute for Endocrine Sciences and Metabolism, Faculty of Medicine, Shahid Beheshti University of
2 Ph.D. of Epidemiology and Biostatistics, Reproductive Endocrinology Research Center, Shahid Beheshti Research Institute for Endocrine Sciences and Metabolism, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
3 Associate Professor, Department of Midwifery and Reproductive Health, School of Nursing and Midwifery, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
4 Professor, Department of Reproductive Endocrinology, Reproductive Endocrinology Research Center, Shahid Beheshti Research Institute for Endocrine Sciences and Metabolism, Faculty of Medicine, Shahid Beheshti University of Medical Sciences,
چکیده [English]

Introduction: Nowadays, selection of a contraceptive with most anti-androgenic effects is an important challenge in treatment of patients with polycystic ovary syndrome (PCOS). This study was performed with aim to compare the effects of Etisterone and Contrasmine pills on PCOS outcomes.
Methods: This randomized clinical trial was conducted between 2016 and 2018, and enrolled 108 patients with PCOS referred to Research institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran. The patients were randomly assigned to one of the intervention groups with Etisterone or Contrasmine pills. The studied outcomes included androgenic, clinical and metabolic parameters at baseline, third and sixth months of treatment. Data collection tools included standard questionnaires, bio-physiologic instruments, and laboratory diagnostic kits. To investigate the differences between the two treatment groups, the statistical model of generalized estimating equations was used. P-value less than 0.05 was considered significant.
Results: After 3 months of treatment, the androgens levels was not significantly different between the two treatment groups (p>0.05), while after 6 months of treatment, the patients treated with Etisterone had lower testosterone levels, compared to those treated with Contrasmine (p=0.029). After 3 months of treatment, the metabolic parameters was not significantly different between the two groups (p>0.05), whereas in 6th month of treatment, patients treated with Etisterone had higher triglyceride levels than those taking Contrasmine (p=0.049). At the end of 3rd and 6th months of treatment, diastolic blood pressure was significantly higher in patients treated with Etisterone, compared to those treated with Contrasmine (p < 0.05).
Conclusion: Use of contraceptives containing cyproterone acetate (CPA) is associated with greater improvement in biochemical hyperandrogenism compared to drospirenone containing products (DRSP), while these compounds can induce hypertriglyceridemia and hypertension in patients with PCOS.

کلیدواژه‌ها [English]

  • Contraceptive
  • Hyperandrogenism
  • Polycystic ovary syndrome (PCOS)
  • Progestin

مراجع

  1. Balen A. Pathogenesis of polycystic ovary syndrome--the enigma unravels?. Lancet 1999; 354(9183):966-967.
  2. Ehrmann DA. Polycystic ovary syndrome. N Engl J Med 2005; 352(12):1223-1236.
  3. Azziz R, Carmina E, Dewailly D, Diamanti-Kandarakis E, Escobar-Morreale HF, Futterweit W, et al. Positions statement: criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome: an Androgen Excess Society guideline. J Clin Endocrinol Metab 2006; 91(11):4237-45.
  4. Barbieri R, Ehrmann D. Diagnosis of polycystic ovary syndrome in adults. UptoDate Sep; 2014.
  5. Vos T, Flaxman AD, Naghavi M, Lozano R, Michaud C, Ezzati M, et al. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. The lancet 2012; 380(9859):2163-96.
  6. Behboudi-Gandevani S, Amiri M, Bidhendi Yarandi R, Noroozzadeh M, Farahmand M, Rostami Dovom M, et al. The risk of metabolic syndrome in polycystic ovary syndrome: A systematic review and meta-analysis. Clin Endocrinol (Oxf) 2018; 88(2):169-184.
  7. Amiri M, Ramezani Tehrani F, Behboudi-Gandevani S, Bidhendi-Yarandi R, Carmina E. Risk of hypertension in women with polycystic ovary syndrome: a systematic review, meta-analysis and meta-regression. Reprod Biol Endocrinol 2020; 18(1):23.
  8. Ramezani Tehrani F, Amiri M, Behboudi-Gandevani S, Bidhendi-Yarandi R, Carmina E. Cardiovascular events among reproductive and menopausal age women with polycystic ovary syndrome: a systematic review and meta-analysis. Gynecol Endocrinol 2020; 36(1):12-23.
  9. Amiri M, Ramezani Tehrani F, Nahidi F, Kabir A, Azizi F, Carmina E. Effects of oral contraceptives on metabolic profile in women with polycystic ovary syndrome: A meta-analysis comparing products containing cyproterone acetate with third generation progestins. Metabolism 2017; 73:22-35.
  10. Amiri M, Nahidi F, Bidhendi-Yarandi R, Khalili D, Tohidi M, Ramezani Tehrani F. A comparison of the effects of oral contraceptives on the clinical and biochemical manifestations of polycystic ovary syndrome: a crossover randomized controlled trial. Hum Reprod 2020; 35(1):175-186.
  11. Amiri M, Ramezani Tehrani P, Ramezani Tehrani F. Effect of interventions based on lifestyle modification on clinical, hormonal and metabolic findings in the patients with polycystic ovary syndrome: a systematic review. Iranian Journal of Endocrinology and Metabolism 2016; 17(6):489-500.
  12. Moran LJ, Noakes M, Clifton PM, Tomlinson L, Galletly C, Norman RJ. Dietary composition in restoring reproductive and metabolic physiology in overweight women with polycystic ovary syndrome. J Clin Endocrinol Metab 2003; 88(2):812-819.
  13. Meyer C, McGrath BP, Teede HJ. Effects of medical therapy on insulin resistance and the cardiovascular system in polycystic ovary syndrome. Diabetes Care 2007; 30(3):471-478.
  14. Palep-Singh M, Mook K, Barth J, Balen A. An observational study of Yasmin in the management of women with polycystic ovary syndrome. J Fam Plann Reprod Health Care 2004; 30(3):163-165.
  15. Bhattacharya SM, Jha A. Comparative study of the therapeutic effects of oral contraceptive pills containing desogestrel, cyproterone acetate, and drospirenone in patients with polycystic ovary syndrome. Fertil Steril 2012; 98(4):1053-1059.
  16. Helvaci N, Yildiz B. Oral contraceptives in polycystic ovary syndrome. Minerva endocrinologica 2014; 39(3):175.
  17. Kahraman K, Sükür YE, Atabekoğlu CS, Ateş C, Taşkın S, Cetinkaya SE, et al. Comparison of two oral contraceptive forms containing cyproterone acetate and drospirenone in the treatment of patients with polycystic ovary syndrome: a randomized clinical trial. Arch Gynecol Obstet 2014; 290(2):321-8.
  18. Gul OB, Somunkiran A, Yucel O, Demirci F, Ozdemir I. The effect of ethinyl estradiol-cyproterone acetate treatment on homocysteine levels in women with polycystic ovary syndrome. Arch Gynecol Obstet 2008; 277(1):25-30.
  19. Vrbíková J, Cibula D. Combined oral contraceptives in the treatment of polycystic ovary syndrome. Hum Reprod Update 2005; 11(3):277-291.
  20. Pehlivanov B, Mitkov M. Efficacy of an oral contraceptive containing drospirenone in the treatment of women with polycystic ovary syndrome. Eur J Contracept Reprod Health Care 2007; 12(1):30-35.
  21. Mathur R, Levin O, Azziz R. Use of ethinylestradiol/drospirenone combination in patients with the polycystic ovary syndrome. Ther Clin Risk Manag 2008; 4(2):487-492.
  22. Kriplani A, Periyasamy AJ, Agarwal N, Kulshrestha V, Kumar A, Ammini AC. Effect of oral contraceptive containing ethinyl estradiol combined with drospirenone vs. desogestrel on clinical and biochemical parameters in patients with polycystic ovary syndrome. Contraception 2010; 82(2):139-146.
  23. Ozdemir S, Görkemli H, Gezginç K, Ozdemir M, Kiyici A. Clinical and metabolic effects of medroxyprogesterone acetate and ethinyl estradiol plus drospirenone in women with polycystic ovary syndrome. Int J Gynaecol Obstet 2008; 103(1):44-49.
  24. De Leo V, Di Sabatino A, Musacchio MC, Morgante G, Scolaro V, Cianci A, et al. Effect of oral contraceptives on markers of hyperandrogenism and SHBG in women with polycystic ovary syndrome. Contraception 2010; 82(3):276-80.
  25. Colonna L, Pacifico V, Lello S, Sorge R, Raskovic D, Primavera G. Skin improvement with two different oestroprogestins in patients affected by acne and polycystic ovary syndrome: clinical and instrumental evaluation. J Eur Acad Dermatol Venereol 2012; 26(11):1364-1371.
  26. Mastorakos G, Koliopoulos C, Deligeoroglou E, Diamanti-Kandarakis E, Creatsas G. Effects of two forms of combined oral contraceptives on carbohydrate metabolism in adolescents with polycystic ovary syndrome. Fertil Steril 2006; 85(2):420-427.
  27. Cagnacci A, Paoletti AM, Renzi A, Orrù M, Pilloni M, Melis GB, et al. Glucose metabolism and insulin resistance in women with polycystic ovary syndrome during therapy with oral contraceptives containing cyproterone acetate or desogestrel. J Clin Endocrinol Metab 2003; 88(8):3621-5.
  28. Falsetti L, Gambera A, Tisi G. Efficacy of the combination ethinyl oestradiol and cyproterone acetate on endocrine, clinical and ultrasonographic profile in polycystic ovarian syndrome. Hum Reprod 2001; 16(1):36-42.
  29. Guido M, Romualdi D, Giuliani M, Suriano R, Selvaggi L, Apa R, et al. Drospirenone for the treatment of hirsute women with polycystic ovary syndrome: a clinical, endocrinological, metabolic pilot study. J Clin Endocrinol Metab 2004; 89(6):2817-23.
  30. Chiazze L Jr, Brayer FT, Macisco JJ Jr, Parker MP, Duffy BJ. The length and variability of the human menstrual cycle. JAMA 1968; 203(6):377-380.
  31. Goodman NF, Cobin RH, Futterweit W, Glueck JS, Legro RS, Carmina E, et al. American Association of Clinical Endocrinologists, American College of Endocrinology, and androgen excess and PCOS society disease state clinical review: guide to the best practices in the evaluation and treatment of polycystic ovary syndrome-part 1. Endocr Pract 2015; 21(11):1291-300.
  32. Treloar AE, Boynton RE, Behn BG, Brown BW. Variation of the human menstrual cycle through reproductive life. Int J Fertil 1967; 12(1 Pt 2):77-126.
  33. Escobar-Morreale HF, Lasunción MA, Sancho J. Treatment of hirsutism with ethinyl estradiol-desogestrel contraceptive pills has beneficial effects on the lipid profile and improves insulin sensitivity. Fertil Steril 2000; 74(4):816-819.
  34. Wang XL, Wang HW, Zhang LL, Guo MX, Huang Z. Topical ALA PDT for the treatment of severe acne vulgaris. Photodiagnosis Photodyn Ther 2010; 7(1):33-38.
  35. Ludwig E. Classification of the types of androgenetic alopecia (common baldness) occurring in the female sex. Br J Dermatol 1977; 97(3):247-254.
  36. Hashemi S, Ramezani Tehrani F, Noroozzadeh M, Azizi F. Normal cut-off values for hyperandrogenaemia in Iranian women of reproductive age. Eur J Obstet Gynecol Reprod Biol 2014; 172:51-55.
  37. Zadeh-Vakili A, Tehrani FR, Hosseinpanah F. Waist circumference and insulin resistance: a community based cross sectional study on reproductive aged Iranian women. Diabetol Metab Syndr 2011; 3:18.
  38. Jonard S, Robert Y, Cortet-Rudelli C, Pigny P, Decanter C, Dewailly D. Ultrasound examination of polycystic ovaries: is it worth counting the follicles?. Hum Reprod 2003; 18(3):598-603.
  39. Raudrant D, Rabe T. Progestogens with antiandrogenic properties. Drugs 2003; 63(5):463-492.
  40. Wiegratz I, Jung-Hoffmann C, Kuhl H. Effect of two oral contraceptives containing ethinylestradiol and gestodene or norgestimate upon androgen parameters and serum binding proteins. Contraception 1995; 51(6):341-346.
  41. Franks S, Layton A, Glasier A. Cyproterone acetate/ethinyl estradiol for acne and hirsutism: time to revise prescribing policy. Hum Reprod 2008; 23(2):231-232.
  42. Fuhrmann U, Krattenmacher R, Slater EP, Fritzemeier KH. The novel progestin drospirenone and its natural counterpart progesterone: biochemical profile and antiandrogenic potential. Contraception 1996; 54(4):243-251.
  43. Mastorakos G, Koliopoulos C, Creatsas G. Androgen and lipid profiles in adolescents with polycystic ovary syndrome who were treated with two forms of combined oral contraceptives. Fertil Steril 2002; 77(5):919-927.
  44. Qin YQ, Jiang FY, Huang KL. Comparison of clinical efficacies of Yasmin and Diane-35 in treatment of polycystic ovary syndrome. Maternal Child Health Care China 2012; 27:1944-7.
  45. Rautio K, Tapanainen J, Ruokonen A, Morin-Papunen L. Effects of metformin and ethinyl estradiol–cyproterone acetate on lipid levels in obese and non-obese women with polycystic ovary syndrome. European journal of endocrinology 2005; 152(2):269-75.
  46. Taylor AE, Keevil B, Huhtaniemi IT. Mass spectrometry and immunoassay: how to measure steroid hormones today and tomorrow. Eur J Endocrinol 2015; 173(2):D1-D12.
مجله زنان، مامایی و نازایی ایران
دوره 23، شماره 6
شهریور 1399
صفحه 29-42

فایل ها

هم رسانی

ارجاع به این مقاله

آمار